IRAKIMID
Dead / Abandoned — Abandoned — no statement of use filed (as of 31 Jul 2023)
What this means for you
This application is over — abandoned 31 Jul 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88754002
- Mark type
- Stylized text
- Filed
- 10 Jan 2020
- Published for opposition
- 05 May 2020
- Abandoned
- 31 Jul 2023
- Attorney of record
- Glenn A. Gundersen
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and medical preparations for the treatment of oncology, autoimmune, immune-oncology and other related diseases; pharmaceutical and medical therapeutics for the treatment of oncology, autoimmune, immune-oncology and other related diseases; diagnostic reagents for the treatment of oncology, autoimmune, immune-oncology and other related diseases
Owner
- Kymera Therapeutics, Inc., Watertown, MA, US
- Kymera Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 31 Jul 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 31 Jul 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 06 Jan 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Jan 2023 — SOU EXTENSION 5 GRANTED
- 29 Dec 2022 — SOU EXTENSION 5 FILED
- 29 Dec 2022 — SOU TEAS EXTENSION RECEIVED
- 30 Jun 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jun 2022 — SOU EXTENSION 4 GRANTED
- 28 Jun 2022 — SOU EXTENSION 4 FILED
- 28 Jun 2022 — SOU TEAS EXTENSION RECEIVED
- 29 Dec 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Dec 2021 — SOU EXTENSION 3 GRANTED
- 27 Dec 2021 — SOU EXTENSION 3 FILED
- 27 Dec 2021 — SOU TEAS EXTENSION RECEIVED
- 02 Jul 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED